ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 191 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2018. The put-call ratio across all filers is 1.26 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $7,233,000 | -33.4% | 100,000 | -39.4% | 4.76% | -32.7% |
| Q4 2017 | $10,864,000 | -27.7% | 165,000 | -45.0% | 7.08% | +70.6% |
| Q3 2017 | $15,036,000 | +224.9% | 300,000 | +200.0% | 4.15% | +58.5% |
| Q2 2017 | $4,628,000 | +74.8% | 100,000 | +33.3% | 2.62% | +99.7% |
| Q1 2017 | $2,648,000 | +139.0% | 75,000 | -6.2% | 1.31% | +561.6% |
| Q3 2016 | $1,108,000 | -6.1% | 80,000 | +60.0% | 0.20% | -57.3% |
| Q3 2015 | $1,180,000 | -90.4% | 50,000 | -66.7% | 0.46% | -88.0% |
| Q2 2015 | $12,264,000 | -33.8% | 150,000 | -25.0% | 3.87% | -50.3% |
| Q1 2015 | $18,520,000 | +129.0% | 200,000 | 0.0% | 7.79% | +99.3% |
| Q4 2014 | $8,088,000 | +164.5% | 200,000 | +60.0% | 3.91% | +139.4% |
| Q3 2014 | $3,058,000 | +54.4% | 125,000 | 0.0% | 1.63% | +76.7% |
| Q2 2014 | $1,980,000 | -3.0% | 125,000 | -7.4% | 0.92% | -2.1% |
| Q1 2014 | $2,041,000 | -1.0% | 135,000 | -10.0% | 0.94% | -19.7% |
| Q4 2013 | $2,061,000 | – | 150,000 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |